Akèy › Leksemi mieloïd egi › Pennsylvania › Pittsburgh
Etid klinik pou Leksemi mieloïd egi nan Pittsburgh, PA
18 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- University of Pittsburgh Medical Center, Pittsburgh
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Ap rekriteFaz 1
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A Study of BGB-11417 in Participants With Myeloid Malignancies
Ap rekriteFaz 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Ap rekriteFaz 3
- US-Pittsburgh PA-PITT, Pittsburgh
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- US-Pittsburgh PA-PITT, Pittsburgh
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Ap rekriteFaz 1
- UMPC Hillman Cancer Center, Pittsburgh
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Ap rekriteFaz 2
- UPMC Hillman Cancer Center, Pittsburgh
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Children's Hospital of Pittsburgh, Pittsburgh
- West Penn Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
- ak 1 plis
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Allegheny Health Network, Pittsburgh
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 2
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè poumon23 etid
- Kansè pwostat23 etid
- Akidan serebavaskilè22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.